Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

107.06 +0.28 (+0.26%)

Streaming Delayed Price Updated: 10:46 AM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Why Merck (MRK) Shares Are Sliding Today

July 29, 2025

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a...

Via StockStory

Topics Artificial Intelligence Workforce

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges ↗

July 29, 2025

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.

Via Benzinga

These S&P500 stocks are gapping in today's session ↗

July 29, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.

Via Chartmill

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Merck & Co's Earnings Outlook ↗

July 28, 2025

Via Benzinga

P/E Ratio Insights for Merck & Co ↗

July 24, 2025

Via Benzinga

Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic ↗

July 21, 2025

Via Stocktwits

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan ↗

July 29, 2025

The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.

Via Stocktwits

Topics World Trade

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided ↗

July 21, 2025

Via Stocktwits

Which S&P500 stocks are moving before the opening bell on Tuesday? ↗

July 29, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

Merck Posts Q2 EPS Beat Revenue Slips ↗

July 29, 2025

Via The Motley Fool

Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations

July 29, 2025

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was...

Via StockStory

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

July 29, 2025

From Merck & Co., Inc.

Via Business Wire

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

July 28, 2025

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.

Via The Motley Fool

Topics Lawsuit

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗

July 28, 2025

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Via Benzinga

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings ↗

July 28, 2025

Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.

Via Benzinga

3 Surprisingly Underrated Stocks to Buy Right Now ↗

July 28, 2025

These big pharma stocks arguably aren't receiving the respect they deserve.

Via The Motley Fool

Topics Intellectual Property

What To Expect From Merck’s (MRK) Q2 Earnings

July 27, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential ↗

July 25, 2025

Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.

Via Chartmill

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗

July 23, 2025

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Via Investor's Business Daily

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

Merck Announces Fourth-Quarter 2025 Dividend

July 22, 2025

From Merck & Co., Inc.

Via Business Wire

MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals ↗

July 22, 2025

MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.

Via Chartmill

Does This Move Make Merck Stock a Buy? ↗

July 20, 2025

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? ↗

July 20, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Want Decades of Passive Income? Buy This ETF and Hold It Forever ↗

July 19, 2025

Via The Motley Fool

Topics ETFs Regulatory Compliance Stocks

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 19, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.